
Gay men in Britain are requesting treatment with Merck & Co Inc's new HPV vaccine Gardasil, with dozens immunized in recent weeks, a London clinic said on Friday.
Gardasil was licensed for use last year against human papillomavirus (HPV) -- a leading cause of cervical cancer in women -- but the sexually transmitted virus can also trigger anal and penile cancers.
"We started offering vaccination to gay men in January and recently we've been giving about 10 a week," said Dr. Sean Cummings of the Freedomhealth clinic in London's Harley Street.
Since many sexually active people are already contaminated with HPV, patients are swabbed before vaccination to determine which, if any, sub-types of HPV they may be carrying.
"If you've got a full house (of HPV sub-types) then there is no point in immunizing," Cummings said.
"The situation in gay men is analogous to the early stages of cervical cancer screening, and the rates of anal cancer in men who have anal sex are akin to those prior to the cervical cancer screening program, at around 35 per 100,000."
However, some experts said the benefits of vaccinating men were not yet clear.
The Terrence Higgins Trust, Britain's leading HIV and AIDS charity, said the case for mass vaccination in men would depend on the outcome of further clinical trials.
Gardasil costs 450 pounds ($880) for a three-dose course at the Freedomhealth clinic, which is highly regarded for its gay men's health service. (Reuters)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
Comments that do not concern specific articles in The Advocate or on Advocate.com will not be posted or published. See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.